Dual Targeted Immunotherapy via In Vivo Delivery of Biohybrid RNAi‐Peptide Nanoparticles to Tumor‐Associated Macrophages and Cancer Cells

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Advanced Functional Materials

• Publication date

  2015-07-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/adfm.201501283PMID 27340392PMCID PMC4914053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomolecular Coronas Provide the Biological Identity of Nanomaterials

  2017cited by this paper
• Suppression of nanoparticle cytotoxicity approaching in vivo serum concentrations: limitations of in vitro testing for nanosafety.

  2014cited by this paper
• Therapeutic Inflammatory Monocyte Modulation Using Immune-Modifying Microparticles

  2014cited by this paper
• Antibody-drug gold nanoantennas with Raman spectroscopic fingerprints for in vivo tumour theranostics.

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma

  2014cited by this paper
• Functional polarization of tumour-associated macrophages by tumour-derived lactic acid

  2014cited by this paper
• Target-responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: the jack-of-all-trades in cancer nanotheranostics?

  2014cited by this paper
• In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight.

  2014cited by this paper
• Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival

  2013cited by this paper
• Tumour-associated macrophages and cancer.

  2013cited by this paper
• Macrophage-specific RNA interference targeting via "click", mannosylated polymeric micelles.

  2013cited by this paper
• In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models.

  2013cited by this paper
• The density of macrophages in colorectal cancer is inversely correlated to TGF-β1 expression and patients’ survival

  2013cited by this paper
• Anti‐tumour strategies aiming to target tumour‐associated macrophages

  2013cited by this paper
• Delivery materials for siRNA therapeutics.

  2013cited by this paper
• Microenvironmental regulation of tumor progression and metastasis

  2013cited by this paper
• Gold-nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events.

  2013cited by this paper
• Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing.

  2012cited by this paper
• Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.

  2012cited by this paper
• Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA.

  2012cited by this paper
• Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation

  2012cited by this paper
• Biomolecular coronas provide the biological identity of nanosized materials.

  2012cited by this paper
• Bronchoalveolar lavage cell pattern from healthy human lung

  2012cited by this paper
• Therapeutic siRNA silencing in inflammatory monocytes

  2011cited by this paper
• Current prospects for RNA interference-based therapies

  2011cited by this paper
• Silencing or stimulation? siRNA delivery and the immune system.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Monocyte recruitment during infection and inflammation

  2011cited by this paper
• Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

  2010cited by this paper
• RNAi nanomedicines: challenges and opportunities within the immune system

  2010cited by this paper
• Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival bearing tumors derived from Brca1-deficient ovarian cancer cells

  2010cited by this paper
• Tumor Site–Specific Silencing ofNF-κB p65by Targeted Hollow Gold Nanosphere–Mediated Photothermal Transfection

  2010cited by this paper
• RNA quantification using gold nanoprobes - application to cancer diagnostics

  2010cited by this paper
• Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells

  2010cited by this paper
• Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution.

  2009cited by this paper
• Small silencing RNAs: state-of-the-art.

  2009cited by this paper
• Knocking down barriers: advances in siRNA delivery

  2009cited by this paper
• Particle size-dependent organ distribution of gold nanoparticles after intravenous administration.

  2008cited by this paper
• Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.

  2008cited by this paper
• Sequence- and target-independent angiogenesis suppression by siRNA via TLR3

  2008cited by this paper
• Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA

  2005cited by this paper
• Tumour-educated macrophages promote tumour progression and metastasis

  2004cited by this paper
• Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells.

  2004cited by this paper
• Cancer and the chemokine network

  2004cited by this paper
• ADVANCED DRUG DELIVERY

  2004cited by this paper
• VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.

  2004cited by this paper
• Tumor progression and metastasis.

  2000cited by this paper
• Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

  1995cited by this paper

• siRNA as a criterion in host immunity and cancer immunotherapy: modulating factors and nano-conjugate based approach for intervention

  2025cites this paper
• Dry powder inhalation of siRNA therapeutics: Emerging strategies for pulmonary gene silencing.

  2025cites this paper
• Emerging cGAS‐STING Agonist‐Based Nanotherapeutics: Mechanistic Insights and Applications in Cancer Combination Therapy

  2025cites this paper
• A review of RNA nanoparticles for drug/gene/protein delivery in advanced therapies: Current state and future prospects.

  2025cites this paper
• Exploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives.

  2025cites this paper
• The progress and perspective of nanomedicine in modulating the tumor immune microenvironment

  2025cites this paper
• Precision engineering of macrophage reprogramming with RNA interference-loaded lipid nanoparticles: a game-changer in cancer immunotherapy.

  2025cites this paper
• Transforming cancer immunotherapy: Overcoming immunosuppression in tumors via gene silencing techniques based on nanoparticles

  2025cites this paper
• Macrophage-centered therapy strategies: a promising weapon in cancer immunotherapy

  2025cites this paper
• Pulmonary Delivery of Nonviral Nucleic Acid‐Based Vaccines With Spotlight on Gold Nanoparticles

  2025cites this paper
• Solvent mediated morphology of ZrZnS nanocrystals for synergistic surface-functionalization with gefitinib and miR146 for cancer treatment

  2025cites this paper
• Peptide based vesicles for cancer immunotherapy: design, construction and applications

  2025cites this paper
• Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy

  2024cites this paper
• Metal-based nanoparticle in cancer treatment: lessons learned and challenges

  2024cites this paper
• Engineering nanomaterials for glioblastoma nanovaccination

  2024cites this paper
• TAM-preferential nanoparticles intracellularly self-assembled for enhanced macrophage repolarization and cancer immunotherapy

  2024cites this paper
• Advances in engineered nanosystems: immunomodulatory interactions for therapeutic applications.

  2024cites this paper
• Harnessing the innate immune system by revolutionizing macrophage-mediated cancer immunotherapy

  2024cites this paper
• Advancements in nanoparticle-based vaccine development against Japanese encephalitis virus: a systematic review

  2024cites this paper
• Alternative routes for parenteral nucleic acid delivery and related hurdles: highlights in RNA delivery

  2024cites this paper
• Unleashing the potential of mRNA: Overcoming delivery challenges with nanoparticles

  2024cites this paper
• Nanotherapeutics for Macrophage Network Modulation in Tumor Microenvironments: Targets and Tools

  2024cites this paper
• Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment.

  2024cites this paper
• Advances in peptide-based drug delivery systems

  2024cites this paper
• Exploring nanocarriers as innovative materials for advanced drug delivery strategies in onco-immunotherapies.

  2024cites this paper
• Polypeptides-Based Nanocarriers in Tumor Therapy

  2024cites this paper
• Reprogramming Tumor-Associated Macrophage Using Nanocarriers: New Perspectives to Halt Cancer Progression

  2024cites this paper
• Advanced gene nanocarriers/scaffolds in nonviral-mediated delivery system for tissue regeneration and repair

  2024cites this paper
• Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy

  2023cites this paper
• Progress in nanoparticle-based regulation of immune cells

  2023cites this paper
• Harnessing biomaterial architecture to drive anticancer innate immunity.

  2023cites this paper
• Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms

  2023cites this paper
• T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems

  2023cites this paper
• Activatable Immunoprotease Nanorestimulator for Second Near-Infrared Photothermal Immunotherapy of Cancer.

  2023cites this paper
• A review on selenium and gold nanoparticles combined photodynamic and photothermal prostate cancer tumors ablation

  2023cites this paper
• Advancements in Macrophage-Targeted Drug Delivery for Effective Disease Management

  2023cites this paper
• Advancing Cancer Treatment Through Nanotechnology Driven Immunotherapy for Pancreatic Cancer

  2023cites this paper
• Data-based modeling of breast cancer and optimal therapy.

  2023cites this paper
• Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy

  2023cites this paper
• Gemcitabine-loaded synthetic high-density lipoprotein preferentially eradicates hepatic monocyte-derived macrophages in mouse liver with colorectal cancer metastases

  2023cites this paper
• Role of Tunable Gold Nanostructures in Cancer Nanotheranostics: Implications on Synthesis, Toxicity, Clinical Applications and Their Associated Opportunities and Challenges

  2023cites this paper
• Targeted DNA Demethylation: Vectors, Effectors and Perspectives

  2023cites this paper
• Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy

  2023cites this paper
• Nanomedicine Combats Drug Resistance in Lung Cancer

  2023cites this paper
• Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy

  2023cites this paper
• Spatial targeting of fibrosis-promoting macrophages with nanoscale metal-organic frameworks for idiopathic pulmonary fibrosis therapy.

  2023cites this paper
• Role of macrophages in cancer progression and targeted immunotherapies.

  2023cites this paper
• Engineered drug delivery nanosystems for tumor microenvironment normalization therapy

  2023cites this paper
• Nanocarrier vaccine therapeutics for global infectious and chronic diseases

  2023cites this paper
• Design of Nanoparticles in Cancer Therapy Based on Tumor Microenvironment Properties

  2022cites this paper
• Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects.

  2022cites this paper
• Chitosan particle stabilized Pickering emulsion/interleukin-12 adjuvant system for Pgp3 subunit vaccine elicits immune protection against genital chlamydial infection in mice

  2022cites this paper
• Hybrid Nanomaterials for Cancer Immunotherapy

  2022cites this paper
• Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy

  2022influential citation
• Homotypic Targeted Photosensitive Nanointerferer for Tumor Cell Cycle Arrest to Boost Tumor Photoimmunotherapy.

  2022cites this paper
• RNA interference (RNAi)-based plasmonic nanomaterials for cancer diagnosis and therapy.

  2022cites this paper
• PTN-PTPRZ1 signaling axis blocking mediates tumor microenvironment remodeling for enhanced glioblastoma treatment.

  2022cites this paper
• Metastasis Role of myeloid cells in the tumor microenvironment

  2022cites this paper
• Recent advances in development of nano-carriers for immunogene therapy in various complex disorders.

  2022cites this paper
• Tracing New Landscapes in the Arena of Nanoparticle-Based Cancer Immunotherapy

  2022cites this paper
• Emerging approaches for enabling RNAi therapeutics.

  2022cites this paper
• Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy

  2022cites this paper
• Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases

  2022influential citation
• Nano-immunotherapeutic strategies for targeted RNA delivery: Emphasizing the role of monocyte/macrophages as nanovehicles to treat glioblastoma multiforme

  2022cites this paper
• Nanodelivery of nucleic acids

  2022cites this paper
• Therapeutic Nanoparticles Harness Myeloid Cells for Brain Tumor-targeted Delivery and Immunomodulation.

  2022cites this paper
• Development of a Localized Drug Delivery System with a Step-by-Step Cell Internalization Capacity for Cancer Immunotherapy.

  2022cites this paper
• Metal (Au)-Decorated Chitosan-l-Arginine Polymeric Vector for Codelivery of Gefitinib and miR125b for Lung Cancer Therapy

  2022cites this paper
• Current Development of Nano-Drug Delivery to Target Macrophages

  2022cites this paper
• Leveraging Macrophages for Cancer Theranostics.

  2022cites this paper
• A comprehensive review on different approaches for tumor targeting using nanocarriers and recent developments with special focus on multifunctional approaches

  2022cites this paper
• Surface Modification of Nanoparticles for Macrophage Targeting

  2022cites this paper
• Challenges and opportunities of nanotechnology in cancer immunotherapy

  2022cites this paper
• Understanding Macrophage-Associated Diseases and Applications of Nanodrug Delivery Systems

  2022cites this paper
• Innovative cancer nanomedicine based on immunology, gene editing, intracellular trafficking control.

  2022cites this paper
• Double-Strand RNA (dsRNA) Delivery Methods in Insects: Diaphorina citri.

  2021cites this paper
• Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy—Current Status and Future Perspectives

  2021cites this paper
• Gold Compounds and the Anticancer Immune Response

  2021cites this paper
• Combinatorial therapy using RNAi and curcumin nano-architectures regresses tumors in breast and colon cancer models.

  2021cites this paper
• Emerging Nanoparticle Strategies for Modulating Tumor-Associated Macrophage Polarization

  2021cites this paper
• Au-siRNA@ aptamer nanocages as a high-efficiency drug and gene delivery system for targeted lung cancer therapy

  2021cites this paper
• Nanoparticles targeting tumor-associated macrophages: A novel anti-tumor therapy

  2021cites this paper
• Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages

  2021cites this paper
• Nanomedicines for Tumor-Associated Macrophages

  2021cites this paper
• Glycosylation of PAMAM dendrimers significantly improves tumor macrophage targeting and specificity in glioblastoma.

  2021cites this paper
• Tailoring Materials for Modulation of Macrophage Fate

  2021cites this paper
• BSA–MnO2–SAL multifunctional nanoparticle-mediated M1 macrophages polarization for glioblastoma therapy

  2021cites this paper
• Nanomedicine-based cancer immunotherapy: recent trends and future perspectives

  2021cites this paper
• Acid-Induced Self-Catalyzing Platform Based on Dextran-Coated Copper Peroxide Nanoaggregates for Biofilm Treatment.

  2021cites this paper
• Remodeling Macrophages by an Iron Nanotrap for Tumor Growth Suppression.

  2021cites this paper
• Strategies to deliver RNA by nanoparticles for therapeutic potential.

  2021cites this paper
• The prospects of Nanotherapeutic approaches for targeting Tumor-Associated Macrophages in oral cancer.

  2021cites this paper
• Advance of nano anticancer therapies targeted on tumor-associated macrophages

  2021cites this paper
• Engineered Iron-Based Nanoplatform Amplifies Repolarization of M2-Like Tumor-Associated Macrophages for Enhanced Cancer Immunotherapy

  2021cites this paper
• Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.

  2021cites this paper
• Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy

  2021cites this paper
• A dual macrophage polarizer conjugate for synergistic melanoma therapy.

  2021cites this paper
• From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer

  2021cites this paper
• Nanomedicines inhibiting tumor metastasis and recurrence and their clinical applications

  2021cites this paper
• Engineered hyaluronic acid-based smart nanoconjugates for enhanced intracellular drug delivery.

  2021cites this paper